General Internal Medicine

Permanent URI for this community

https://scholar.sun.ac.za/handle/10019.1/161

Browse

Browsing General Internal Medicine by browse.metadata.advisor "Moolman-Smook, J. C."

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    The role of phosphatase activity and expression in glucocorticoid modulation of preosteoblasts
    (Stellenbosch : University of Stellenbosch, 2011-12) Sanderson, Micheline; Ferris, W. F.; Moolman-Smook, J. C.; University of Stellenbosch. Faculty of Health Sciences. Dept. of Medicine. Internal Medicine.
    ENGLISH ABSTRACT: The increase in the prescription and use of glucocorticoids (GCs) to treat various diseases and resulting decrease in bone density and development of osteoporosis is of growing concern. Glucocorticoid-induced osteoporosis (GCIO) is a relatively under-researched disease with the mechanism by which GCs affect bone metabolism not yet fully delineated. This holds especially true for the early events in bone development. The negative effects of GCs are predominantly seen in osteoblasts, the cells responsible for bone formation, in that GCs diminish both the numbers and function of osteoblastic cells. Osteoblast precursor cell proliferation is crucial to ensure the existence of a healthy pool of osteoblastic cells needed to form new bone after bone resorption by osteoclasts. Previously, it was shown that GCs reduce the proliferation of immortalised osteoblastic cell lines. In addition, early immortalised preosteoblasts were more sensitive to GCs than their mature counterparts. However, these cells have corrupted cell cycles; therefore, primitive primary mesenchymal stromal cells (MSCs) were used in this study to examine the effect of GCs on the mitogen-induced proliferation of early osteoblast precursor cells (naïve MSCs and preosteoblasts) using the synthetic GC, dexamethasone (Dex). Mitogenic conditions established for naïve rat mesenchymal stromal cells (rMSCs) indicated that mild (5% FBS) stimulation is sufficient to induce proliferation, whereas a higher FBS concentration (20% FBS) was mitogenic in primary preosteoblasts. It was also found that pharmacological doses of Dex drastically decreased the mitogen-induced proliferation of both naïve rat MSCs (rMSCs) and preosteoblasts. Mitogen-activated protein kinase (MAPK) signalling pathways, such as ERK1/2, govern cell proliferation. GCs have been shown to decrease the activity of ERK1/2, which is associated with decreased proliferation in osteoblastic cells. In the present study, western blot analysis showed that Dex reduced the proliferation-associated shoulder of the ERK1/2 activity profile in both naïve rMSCs and preosteoblasts. Moreover, the ERK1/2 signalling pathway was shown to be essential for mitogen-stimulated growth of naïve rMSCs and preosteoblasts as the MEK1/2 inhibitor, U0126, inhibited mitogen-induced proliferation. Using western blot analysis, it was shown that, after mitogen administration, ERK1/2 activity exhibited a typical proliferation profile, which was blocked by U0126. Protein tyrosine phosphatases (PTPs) dephosphorylate and inactivate ERK1/2. Utilising sodium vanadate, an inhibitor of PTPs, in vitro phosphatase assays revealed that PTP activity was the predominant phosphatase activity present in naïve rMSCs and preosteoblast lysates after concomitant mitogen and Dex stimulation. The mRNA of the dual specificity phosphatase, MKP-1, was rapidly (within 30 minutes) upregulated after mitogen and Dex administration in both naïve rMSCs and preosteoblasts. However, the protein expression pattern of MKP-1 did not correspond to the mRNA induction, suggesting that the MKP-1 protein could be subjected to rapid degradation. These findings suggest that MKP-1 could possibly be involved in the GC regulation of mitogen-induced proliferation of early osteoblast precursor cells, but closer investigation is needed to fully elucidate this role. In addition, the involvement of other PTPs should not be excluded and warrants further investigation. During the course of the present study, it was found that strong mitogenic stimulation with 20% FBS led to oncogene-induced senescence (OIS). Flow cytometry analysis revealed the presence of two populations in naïve rMSCs preparations and DNA content analysis was consistent with that of cells undergoing OIS. These results indicated that the more primitive osteoblast precursor cells (naïve rMSCs) are more responsive to mitogens than their mature counterparts (preosteoblasts). In addition, it was found that the magnitude of ERK1/2 activation was increased in naïve rMSC after strong mitogenic stimulation, indicating that naïve rMSCs are still highly sensitive to stimulation with strong mitogens. In summary, these findings show that Dex decreased the proliferation of naïve rMSCs and preosteoblasts concomitantly with a decrease in ERK1/2 activity. In addition, Dex upregulated MKP-1 mRNA, but the same effect was not seen on the MKP-1 protein levels. Therefore, this suggests that PTP/s other than MKP-1 could be responsible for the inactivation of ERK1/2 by Dex, leading to decreased proliferation in naïve rMSCs and preosteoblasts. Further identification of PTPs that regulate osteoblast precursor cell numbers and function could lead to the elucidation of the mechanism through which GCs act to negatively influence bone density. This will improve our insights into the pathogenesis of GCIO and aid in the identification of therapeutic targets which can be exploited to develop new agents to treat osteoporosis.